期刊文献+

萘哌地尔衍生物(BWYJ)抗小鼠前列腺增生作用 被引量:1

Effect of Naftopidil ramification-BWYJ on benign prostatic hyperplasia in mice
下载PDF
导出
摘要 目的观察萘哌地尔衍生物(BWYJ)对丙酸睾酮诱发的小鼠良性前列腺增生(BPH)模型的影响。方法激素法诱发小鼠前列腺增生,称重法测定前列腺湿重,计算前列腺指数;光镜和电镜下观察前列腺组织形态及超微结构的变化,并进行形态定量学分析。结果5、10、20 mg.kg-1BWYJ治疗3 w后,可降低BPH小鼠前列腺湿重指数,且较高剂量下疗效与保列治相当。光镜下可见,BWYJ剂量依赖性地使增生的腺上皮乳头减少或消失,上皮细胞呈低立方或扁平状;图像分析显示:BWYJ 10和20 mg.kg-1使BPH小鼠前列腺腺体平均最小直径、最大直径及平均面积均减小(P<0.05)。电镜下:BWYJ治疗组腺上皮细胞排列规整,呈低柱状,有微绒毛脱落及凋亡小体存在。结论BWYJ具有抗小鼠BPH作用。 Objective To observe the effect of Naftopidil ramification-BWYJ on mice model of benign prostatic hyperplasia (BPH) induced by testosterone propionate. Methods BPH mice were induced by testosterone propionate to detect prostatic wet weight and calculate prostatic index. As well morphological and ultrastructure changes of prostate were observed through light and electron microscope to conduct semi-quantified by image analysis system. Results Prostate wet weight index decreased 3 weeks after treated by BWYJ at dose of 5, 10 and 20 mg/kg. Under light-microscope, BWYJ decreased hyperplasia epithelia and papillary configuration by dose-dependency; the epithelium were cubical or flatty. Imaging analysis showed 10 and 20 mg/kg BWYJ decreased average minimum and maximal diameter and area ( P 〈 0.05). Under electron microscope the epithelia were lined regularly with nuclear lied at the base of cells, the nucleus even removed to the top of epithelia and dropped into the glandular lumina in BWYJ group. Conclusions BWYJ could play inhibiting role in BPH.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2006年第5期630-633,共4页 Chinese Journal of Gerontology
基金 国家自然科学基金资助(NO30060087) 贵州省科技基金重点项目(计〔2002(3014)〕资助课题
关键词 萘哌地尔衍生物 前列腺增生 形态定量学 超微结构 BWYJ Benign prostatic hyperplasia (BPH) Histomorphology Uhrastructure
  • 相关文献

参考文献7

二级参考文献39

  • 1[1]Peter G,Niebch G,Locher M,et al.Pharmacokinetic fate of the novel antihypertensive drug naftopidil[J].Arzneimittelforschun g,1991,41(9)∶924-93 1.
  • 2[2]Niebch G,Locher M,Borbe HO.Metabolic fate of the novel antihypert ensive drug naftopidil[J].Arzneimittelforschung,1991,41(10)∶1027-1032.
  • 3[3]Borbe HO,Peter G.Radioreceptor assay for the determination of alp ha1-adr enoceptor-binding material in rat plasma following single oral administration o f naftopidil[J].Arzneimittelforschung,1990,40(3)∶253-256.
  • 4[4]Niebch G, Borbe HO,Besenfelder E.High-performance liquid chromat ography of naftopidil,a novel antihypertensive drug, and two metabolites in human plasm a[J].J Chromatogr,1990,534∶247-252.
  • 5[5]Terakado T,Oki E,Iida M,et al.Metabolism of naftopidil (KT-6 11) in healthy volunteers[J].J Clin Ther Med,1992,8(Suppl 3)∶S3-S9.
  • 6[6]NN.Naftopidil:Investigational Drug Brochure[R].ASTA Medica AG,1 992.
  • 7[7]Takagi N,Ishii M,Takeda K,et al.Pharmacokinetics of naftopidi l (KT-6 11) in hypertensive patients with renal impairment or normal renal function[J] .J Clin Ther Med,1992,8(Suppl 3)∶S109-S122.
  • 8[8]Farthing MJ,Alstead EM,Abrams SM,et al.Pharmacokinetics of na ftopidil ,a novel anti-hypertensive drug,in patients with hepatic dysfunction[J].Pos tgrad Med J,1994,70(823)∶363-366.
  • 9[9]Sponer G,Borbe HO,Muller-Beckmann B,et al.Naftopidil,a new a drenocep tor blocking agent with Ca(2+)-antagonistic properties:interaction with adrenoc eptors[J].J Cardiovasc Pharmacol,1992,20(6)∶1006-1013.
  • 10[10]Muramatsu I,Yamanaka K,Kigoshi S.Pharmacological profile of the novel al pha-adrenoceptor antagonist KT-611 (naftopidil)[J].Jpn J Pharmacol,1991, 55(3)∶391-398.

共引文献61

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部